A Phase 3 interventional study of Aripiprazole in Bipolar I, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 142 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-21.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder. The trial will enroll subjects who completed Trial 31-08-250 and de novo subjects not participating in Trial 31-08-250.
This will be an open-label, uncontrolled study which will enroll subjects completing Study 31-08-250 and new subjects. The treatment history of subjects prior to enrollment in the open-label study will vary according to the design of the pivotal double-blind study (i.e 31-08-250).
This open-label study will be comprised of phases similar to the pivotal double-blind study (i.e. Study 250): a screening phase (if applicable), a conversion phase (Phase A, if applicable), an oral stabilization phase (Phase B, if applicable), and an IM depot open-label maintenance phase (Phase C). Phase C will be a minimum of 28 weeks up to a 52-week treatment period with a 4 week follow up period.
During Phase C (the open-label maintenance phase) rescue medication will be allowed for subjects who do not meet stability criteria. This analysis focuses on Phase C due to ClinicalTrials.gov system limitations.
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole, Intramuscular (IM) Depot
Drug: Aripiprazole
400mg or 300mg, intramuscular injections every 4 weeks.
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP). AEs were assessed as a criteria for safety and tolerability.
Time frame: Up to Week 52
Injection Site Pain Measured by the Visual Analog Scale (VAS)
Injection-site pain was evaluated by mean visual analog scale (VAS) scores as reported by the participant after each injection at visits where an injection occurred. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
Time frame: Up to Week 52
Number of Participants With Clinically Significant Abnormal Laboratory Test Results
Standard safety variables to be analyzed included clinical laboratory tests. Incidence of treatment emergent adverse events (TEAEs) of potential clinical relevance included abnormal values in serum chemistry, hematology, urinalysis, and other laboratory test that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as serious adverse event/adverse events (SAE/AEs) and are reported in the SAE/other AE section of this report.
Time frame: Up to Week 52
Number of Participants With Clinically Significant Abnormal Vital Signs
TEAEs of potential clinical relevance included abnormal values in body weight, systolic and diastolic blood pressure, heart rate, and body temperature that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
Time frame: Up to Week 52
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)
Twelve-lead ECGs were recorded at specified visits. For each time point, three 12-lead ECG recordings were obtained approximately 5 minutes apart. Additional 12-lead ECGs were permitted to be obtained at the investigator's discretion and were to always be obtained in the event of an early termination. The ECGs were evaluated at the investigational site to determine the participant's eligibility and to monitor safety during the trial.
Time frame: Up to Week 52
Extrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)
AIMS: 10 items described dyskinesia signs; 0-absence/no awareness; 4-severe condition/severe distress. Total score for Items 1-10 ranges from 0 to 40; a higher score reflects severe condition. SAS:Consisted of 10 parkinsonism signs;1-no symptoms;5-severe.Total score for Items 1-10 ranges from 1 to 50;a higher score reflects severe condition.DIEPSS:A 9-item rating scale (8 assessed individual symptoms \[4 categories of parkinsonism, akathisia, dystonia \& dyskinesia\]+1 assessed general severity) was used;0-no symptoms/normal, 4-severe.Total score (8 individual symptom items) was in range of 0 to 32 (a higher score reflects severe condition).BARS:Consisted of 4 items related to akathisia:objective observation, subjective feelings of restlessness, distress, global clinical evaluation.Only BARS global clinical assessment score has been presented and rated using scale:0-absence of symptoms;5-severe akathisia.Total BARS global score ranges from 0 to 5,a higher score reflects severe condition.
Time frame: Baseline, Week 28, and Week 52
Number of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)
Suicidality was monitored throughout the trial using the C-SSRS at every visit. The C-SSRS scale consisted of a screening/baseline evaluation that assessed the participant's lifetime experience and experience over the last 90 days with suicide events and suicidal ideation and a post-baseline/ "Since Last Visit" evaluation that focused on suicidality since the last trial visit.
Time frame: Up to Week 52
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe) . The participant indicated the degree of pain at the most recent injection site using a VAS. Ratings ranged from 0 (no pain) to 100 (unbearably painful). Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. These assessments occurred at trial visits where injections occurred (scheduled and unscheduled), beginning with the first dose of open-label aripiprazole IM depot administered at the final visit of the Oral Stabilization Phase and continued through the last injection prior to the end of the IM Depot Maintenance Phase/Early termination (ET) visit (ie, evaluations were not done at end of the IM Depot Maintenance Phase/ET visit).
Time frame: Up to Week 52
Percentage of Participants Who Remained Stable at End of Treatment in Phase C
The secondary objective was to evaluate the efficacy, as measured by the percentage of stable participants at baseline who remained stable at the end of treatment in the IM depot maintenance phase, of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to subjects with bipolar I disorder.
Time frame: Up to Week 52
This open-label, single-arm, uncontrolled trial evaluated aripiprazole intramuscular (IM) depot as maintenance treatment for participants with bipolar I disorder. Enrolled participants included those who had completed Trial 31-08-250 (NCT01567527) as well as de novo participants who had not participated in Trial 31-08-250.
| Milestone | Phase C: Open-Label IM Depot Maintenance Phase |
|---|---|
| Started | 464 |
| Completed | 291 |
| Not completed | 173 |
| Withdrew: Lost to follow-up | 29 |
| Withdrew: Adverse event | 48 |
| Withdrew: Participant met withdrawal criteria | 33 |
| Withdrew: Participant withdrawn by investigator | 2 |
| Withdrew: Withdrawal by subject | 53 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Lack of efficacy | 3 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP). AEs were assessed as a criteria for safety and tolerability.
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Participants with adverse events | 374 |
| Participants with TEAEs | 374 |
| Participants with serious TEAEs | 30 |
| Participants with severe TEAEs | 41 |
| Participants discontinued from IMP due to AEs | 47 |
| Participants discont. from IMP due to AEs or death | 48 |
| Deaths | 1 |
Injection-site pain was evaluated by mean visual analog scale (VAS) scores as reported by the participant after each injection at visits where an injection occurred. Ratings ranged from 0 (no pain) to 100 (unbearably painful).
| Units on a scale | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| 1ST Injection | 4.9 ± 10.7 |
| 2ND Injection | 4.1 ± 8.4 |
| 3RD Injection | 3.4 ± 7.5 |
| 4TH Injection | 3.6 ± 8.6 |
| 5TH Injection | 2.9 ± 7.9 |
| 6TH Injection | 2.4 ± 5.8 |
| 7TH Injection | 2.6 ± 7.0 |
| 8TH Injection | 2.4 ± 4.9 |
| 9TH Injection | 2.6 ± 6.6 |
| 10TH Injection | 2.5 ± 7.5 |
| 11TH Injection | 2.4 ± 6.3 |
| 12TH Injection | 1.8 ± 4.3 |
| 13TH Injection | 2.2 ± 5.5 |
| Last Injection | 2.4 ± 5.9 |
Standard safety variables to be analyzed included clinical laboratory tests. Incidence of treatment emergent adverse events (TEAEs) of potential clinical relevance included abnormal values in serum chemistry, hematology, urinalysis, and other laboratory test that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as serious adverse event/adverse events (SAE/AEs) and are reported in the SAE/other AE section of this report.
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Fasting cholesterol | 53 |
| Fasting glucose | 39 |
| Fasting low-density lipoprotein cholesterol | 32 |
| Fasting triglycerides | 124 |
TEAEs of potential clinical relevance included abnormal values in body weight, systolic and diastolic blood pressure, heart rate, and body temperature that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Weight gain of ≥ 7% | 93 |
| Weight loss of ≥ 7% | 66 |
| Blood pressure increased | 4 |
| Heart rate increased | 3 |
| Blood pressure decreased | 2 |
| Body temperature | 0 |
Twelve-lead ECGs were recorded at specified visits. For each time point, three 12-lead ECG recordings were obtained approximately 5 minutes apart. Additional 12-lead ECGs were permitted to be obtained at the investigator's discretion and were to always be obtained in the event of an early termination. The ECGs were evaluated at the investigational site to determine the participant's eligibility and to monitor safety during the trial.
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Symmetrical T-wave inversion | 9 |
| Supraventricular premature beat | 8 |
| Ventricular premature beat | 4 |
| Myocardial ischemia | 2 |
AIMS: 10 items described dyskinesia signs; 0-absence/no awareness; 4-severe condition/severe distress. Total score for Items 1-10 ranges from 0 to 40; a higher score reflects severe condition. SAS:Consisted of 10 parkinsonism signs;1-no symptoms;5-severe.Total score for Items 1-10 ranges from 1 to 50;a higher score reflects severe condition.DIEPSS:A 9-item rating scale (8 assessed individual symptoms \[4 categories of parkinsonism, akathisia, dystonia \& dyskinesia\]+1 assessed general severity) was used;0-no symptoms/normal, 4-severe.Total score (8 individual symptom items) was in range of 0 to 32 (a higher score reflects severe condition).BARS:Consisted of 4 items related to akathisia:objective observation, subjective feelings of restlessness, distress, global clinical evaluation.Only BARS global clinical assessment score has been presented and rated using scale:0-absence of symptoms;5-severe akathisia.Total BARS global score ranges from 0 to 5,a higher score reflects severe condition.
| Units on a scale | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| AIMS, Week 28 | 0.07 ± 1.00 |
| AIMS, Week 52 | 0.05 ± 0.97 |
| SAS, Week 28 | 0.21 ± 1.59 |
| SAS, Week 52 | 0.20 ± 1.58 |
| DIEPSS, Week 28 | 0.32 ± 1.29 |
| DIEPSS, Week 52 | 0.21 ± 1.11 |
| BARS, Week 28 | 0.05 ± 0.61 |
| BARS, Week 52 | 0.04 ± 0.60 |
Suicidality was monitored throughout the trial using the C-SSRS at every visit. The C-SSRS scale consisted of a screening/baseline evaluation that assessed the participant's lifetime experience and experience over the last 90 days with suicide events and suicidal ideation and a post-baseline/ "Since Last Visit" evaluation that focused on suicidality since the last trial visit.
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Completed Suicide | 0 |
| Suicide Attempt | 3 |
| Preparatory action toward imminent suicide | 4 |
| Suicidal ideation | 46 |
| Non-suicidal self-injurious behavior | 4 |
Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe) . The participant indicated the degree of pain at the most recent injection site using a VAS. Ratings ranged from 0 (no pain) to 100 (unbearably painful). Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. These assessments occurred at trial visits where injections occurred (scheduled and unscheduled), beginning with the first dose of open-label aripiprazole IM depot administered at the final visit of the Oral Stabilization Phase and continued through the last injection prior to the end of the IM Depot Maintenance Phase/Early termination (ET) visit (ie, evaluations were not done at end of the IM Depot Maintenance Phase/ET visit).
| Participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Injection Site Bruising | 2 |
| Injection Site Erythema | 1 |
| Injection Site Induration | 1 |
| Injection Site Mass | 2 |
| Injection Site Pain | 34 |
| Injection Site Swelling | 4 |
The secondary objective was to evaluate the efficacy, as measured by the percentage of stable participants at baseline who remained stable at the end of treatment in the IM depot maintenance phase, of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to subjects with bipolar I disorder.
| Percentage of participants | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Baseline | 100.00 |
| Week 2 | 96.98 |
| Week 4 | 97.22 |
| Week 8 | 95.64 |
| Week 12 | 96.31 |
| Week 16 | 96.46 |
| Week 20 | 95.54 |
| Week 24 | 96.40 |
| Week 28 | 95.09 |
| Week 32 | 97.91 |
| Week 36 | 95.94 |
| Week 40 | 98.04 |
| Week 44 | 97.59 |
| Week 48 | 97.53 |
| Week 52 | 95.78 |
| Last Visit | 88.91 |
Collected over Phase C week 1 to week 52/early termination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase C: Open-Label IM Depot Maintenance Phase | 1/464 (0.2%) | 30/464 (6.5%) | 367/464 (79.1%) |
| Event | Phase C: Open-Label IM Depot Maintenance Phase |
|---|---|
| Bipolar I DisorderPsychiatric disorders | 4/464 |
| Suicidal IdeationPsychiatric disorders | 4/464 |
| ManiaPsychiatric disorders | 3/464 |
| Chest PainGeneral disorders | 2/464 |
| Bipolar DisorderPsychiatric disorders | 2/464 |
| Acute Myocardial InfarctionCardiac disorders | 1/464 |
| Cardiac ArrestCardiac disorders | 1/464 |
| Myocardial InfarctionCardiac disorders | 1/464 |
| Prinzmetal AnginaCardiac disorders | 1/464 |
| HyperprolactinaemiaEndocrine disorders | 1/464 |
| Event | Phase C: Open-Label IM Depot Maintenance Phase |
|---|---|
| AkathisiaNervous system disorders | 68/464 |
| Weight increasedInvestigations | 62/464 |
| NasopharyngitisInfections and infestations | 56/464 |
| InsomniaPsychiatric disorders | 51/464 |
| AnxietyPsychiatric disorders | 46/464 |
| Injection site painGeneral disorders | 34/464 |
| HeadacheNervous system disorders | 29/464 |
| TremorNervous system disorders | 28/464 |
| DepressionPsychiatric disorders | 26/464 |
| Upper respiratory tract infectionInfections and infestations | 24/464 |
| Age, Categorical(Participants) | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 458 |
| >=65 years | 6 |
| Age, Continuous(Years) | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Mean | 41.1 ± 11.8 |
| Sex: Female, Male(Participants) | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Female | 268 |
| Male | 196 |
| Region of Enrollment(Participants) | Phase C: Open-label IM Depot Maintenance Phase |
|---|---|
| Canada | 3 |
| South Korea | 6 |
| Romania | 10 |
| Hungary | 4 |
| United States | 322 |
| Japan | 75 |
| Taiwan | 1 |
| Poland | 28 |
| Malaysia | 10 |
| France | 5 |
Showing the first 100 of 142 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2012, a primary completion of Nov 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →